Sector News

MedImmune, Abpro create new firm

November 30, 2016
Life sciences

AstraZeneca’s biologics research and development arm MedImmune and US life sciences group Abpro have spun out a new company to advance development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).

Abpro will oversee day-to-day leadership of the new group, AbMed, which will explore several potential therapeutic areas where inhibition of the Ang2 and VEGF pathways with this unique bispecific antibody may provide clinical benefit.

The antibody, which was engineered by scientists at MedImmune, has demonstrated potent activity in animal models, which may be useful in targeting disease indications with high unmet needs, the firms note.

Abpro will use its scientific, technical and clinical expertise to drive forward the new firm and its technology platform, DiversImmune, to further refine the antibody.

Under the terms of the deal, AbMed, which will operate as a subsidiary of Abpro, will receive majority global development and commercialisation rights to the program, and MedImmune development, regulatory and sales milestones and royalties, as well as hold a minority equity stake in AbMed.

“This agreement arises out of MedImmune’s culture of entrepreneurship and innovation — both in science and in business,” said Jane Osbourn, vice president of R&D at MedImmune. “We believe partners like Abpro can help us maximise our extensive pre-clinical portfolio to advance therapies for patients.”

By Selina McKee

Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).